Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...

A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and ...

BENGALURU: Dermatologists in Bengaluru are reporting an increase in psoriasis cases during the ongoing winter season, with both new patients and those previousl ...

Johnson & Johnson wins EU approval for Tremfya in pediatric plaque psoriasis, making it the first IL-23 inhibitor cleared for any pediatric condition.

Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the two pivotal Phase 3 randomized, ...

If you or someone close to you is dealing with a chronic skin condition like psoriasis, following the right dietary habits is ...

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Positive Results for SGX302 in Cohort 3 of Phase 2a Psoriasis Trial ...

Vanda Pharmaceuticals (VNDA) stock hit a two-year high on news it filed a FDA application for its psoriasis drug ...

That's because the natural ingredient is known as a superfood that can literally transform your body from the inside out, but ...

Belgium: Johnson & Johnson has announced that the European Commission has extended the marketing authorisation for TREMFYA ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...